Compensatory contribution of Cav2.3 channels to acetylcholine release at the neuromuscular junction of tottering mice.
Tottering (Tg) mice carry the mutation P601L in their Cacna1a encoded Cav2.1 channels. Transmitter release at the wild-type neuromuscular junction (NMJ) is almost exclusively mediated by Cav2.1 channels, and we used this model synapse to study synaptic consequences of the Tg mutation. With electrophysiology, and using subtype-specific Cav2 channel-blocking toxins, we assessed a possible compensatory contribution of non-Cav2.1 channels to evoked acetylcholine (ACh) release at Tg NMJs. Release was reduced by approximately 75% by the Cav2.1 channel blocker omega-agatoxin-IVA, which was less than the approximately 95% reduction observed in wild-type. Release at Tg NMJs, but not at wild-type synapses, was reduced by approximately 15% by SNX-482, a Cav2.3 channel blocker. No Cav2.2 channel involvement was found. Probably, there is a small reduction in functional presynaptic Cav2.1 channels at Tg NMJs, which is compensated for by Cav2.3 channels. The remaining Cav2.1 channels are likely to convey enlarged Ca2+ flux, because evoked ACh release at Tg NMJs, at low extracellular Ca2+ concentration, was approximately sixfold higher than at wild-type NMJs. This is the first report of compensatory expression of non-Cav2.1 channels at NMJs of mice with a single amino acid change in Cav2.1.
Kaja
Simon
S
Department of Neurology, Leiden University Medical Centre, Leiden, The Netherlands.
Van de Ven
Rob C G
RC
Ferrari
Michel D
MD
Frants
Rune R
RR
Van den Maagdenberg
Arn M J M
AM
Plomp
Jaap J
JJ
D000109:Acetylcholine / Q000378:metabolism*; D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000818:Animals; D002118:Calcium / Q000032:analysis / Q000494:pharmacology; D002121:Calcium Channel Blockers / Q000494:pharmacology; D020864:Calcium Channels, N-Type / Q000032:analysis / Q000502:physiology; D020865:Calcium Channels, P-Type / Q000235:genetics* / Q000502:physiology; D020907:Calcium Channels, Q-Type / Q000235:genetics* / Q000502:physiology; D020908:Calcium Channels, R-Type / Q000502:physiology*; D027682:Cation Transport Proteins / Q000502:physiology*; D004594:Electrophysiology; D005071:Evoked Potentials / Q000187:drug effects / Q000502:physiology; D051379:Mice; D008817:Mice, Mutant Strains; D009154:Mutation; D009469:Neuromuscular Junction / Q000737:chemistry / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D013111:Spider Venoms / Q000494:pharmacology; D013569:Synapses / Q000502:physiology; D020867:omega-Agatoxin IVA / Q000494:pharmacology
D000109:Acetylcholine; D002118:Calcium; D002121:Calcium Channel Blockers; D020864:Calcium Channels, N-Type; D020865:Calcium Channels, P-Type; D020907:Calcium Channels, Q-Type; D020908:Calcium Channels, R-Type; D027682:Cation Transport Proteins; D013111:Spider Venoms; D020867:omega-Agatoxin IVA; C500963:Cacna1b protein, mouse; C498916:Cacna1e protein, mouse; C115521:SNX 482